基于风险分层的缺血性卒中后72小时内双联抗血小板治疗:一项事后分析
该研究为INSPIRES随机临床试验的事后分析,纳入6100例急性轻型缺血性卒中或高危短暂性脑缺血发作患者,按Essen卒中风险评分(ESRS)及改良ESRS分层。结果显示,ESRS<3分的患者从72小时内启动氯吡格雷-阿司匹林治疗中获益更大(HR 0.67,95%CI 0.52-0.86),而ESRS≥3分者未见显著获益(HR 0.92,95%CI 0.72-1.18),交互作用P=0.07。
要点
- ESRS<3分的急性轻型卒中或高危TIA患者,72小时内氯吡格雷-阿司匹林较单用阿司匹林降低90天新发卒中风险(HR 0.67)。
- ESRS≥3分患者中,氯吡格雷-阿司匹林与单用阿司匹林相比新发卒中风险无显著差异(HR 0.92,95%CI 0.72-1.18)。
- 中重度出血风险在各风险分层亚组间无显著交互作用(ESRS分层Pinteraction=0.21)。
核心结论
- 基于ESRS评估的低风险特征患者,在症状发作后72小时内启动氯吡格雷-阿司匹林治疗较单用阿司匹林获益更大。
研究设计与样本
- INSPIRES随机临床试验的二次事后分析,纳入2018年至2022年年龄35至80岁的急性轻型缺血性卒中或高危短暂性脑缺血发作患者,共6100例,氯吡格雷-阿司匹林组与阿司匹林组各3050例。
- 患者依据Essen卒中风险评分(ESRS)及改良ESRS进行风险分层。
主要发现
- ESRS<3分患者中,氯吡格雷-阿司匹林组较阿司匹林组降低90天新发卒中风险(HR 0.67,95%CI 0.52-0.86);ESRS≥3分患者中两组无显著差异(HR 0.92,95%CI 0.72-1.18),交互作用P=0.07。
- 改良ESRS分层:男性<6分且女性<5分患者HR 0.68(95%CI 0.55-0.83);男性≥6分且女性≥5分患者HR 1.14(95%CI 0.82-1.59),交互作用P=0.01。
- 中重度出血:ESRS<3分组HR 1.35(95%CI 0.54-3.35),ESRS≥3分组HR 3.21(95%CI 1.18-8.78),交互作用P=0.21;改良ESRS低分组HR 1.96(95%CI 0.88-4.36),高分组HR 2.27(95%CI 0.70-7.39),交互作用P=0.85。
临床怎么用
- 作者认为,基于ESRS评估为低风险特征的患者,在症状发作后72小时内启动氯吡格雷-阿司匹林治疗较单用阿司匹林获益更大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risk profile of recurrence may influence the effect of antiplatelet therapy. This study aimed to evaluate the efficacy and safety of clopidogrel-aspirin initiated within 72 hours after symptom onset for acute mild stroke or high-risk transient ischemic attack stratified by risk profile. METHODS: This is a secondary post hoc analysis of the INSPIRES (Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis) randomized clinical trial that enrolled patients 35 to 80 years old with acute mild ischemic stroke or high-risk transient ischemic attack between 2018 and 2022. Patients were stratified into different groups based on the Essen Stroke Risk Score (ESRS) and modified ESRS. The primary efficacy outcome was any new stroke within 90 days. The primary safety outcome was moderate-to-severe bleeding within 90 days. RESULTS: Among 6100 patients (3050 each in the clopidogrel-aspirin group and aspirin group), the median age was 65 years (interquartile range, 57-71 years), and 3915 (64.2%) were male. Clopidogrel-aspirin was associated with a reduced risk of new stroke in patients with an ESRS of <3 (hazard ratio [HR], 0.67 [95% CI, 0.52-0.86]), but not in those with an ESRS of ≥3 (HR, 0.92 [95% CI, 0.72-1.18]), compared with aspirin (Pinteraction=0.07). Similar results were found in patients stratified by modified ESRS (modified ESRS <6 in male and <5 in female: HR, 0.68 [95% CI, 0.55-0.83]; modified ESRS ≥6 in male and ≥5 in female: HR, 1.14 [95% CI, 0.82-1.59]; Pinteraction=0.01). The association between antiplatelet therapy and the moderate-to-severe bleeding did not differ across risk profile subgroups (ESRS of <3: HR, 1.35 [95% CI, 0.54-3.35]; ESRS of ≥3: HR, 3.21 [95% CI, 1.18-8.78]; Pinteraction=0.21; modified ESRS of <6 in male and <5 in female: HR, 1.96 [95% CI, 0.88-4.36]; modified ESRS of ≥6 in male and ≥5 in female: HR, 2.27 [95% CI, 0.70-7.39]; Pinteraction=0.85). CONCLUSIONS: This post hoc analysis of the INSPIRES trial showed that patients with a low level of risk profile assessed by ESRS received greater benefit from clopidogrel-aspirin initiated within 72 hours after symptom onset than aspirin alone. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03635749.
引用
- Zhang Y, Wang X, Gao Y, et al. Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke Stratified by Risk Profile: A Post Hoc Analysis. Stroke. 2024. PMID: 39705390. doi:10.1161/STROKEAHA.124.049246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。